Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026
About this episode
This episode discusses the potential of fenebrutinib as a treatment for primary progressive multiple sclerosis based on recent clinical trial results.
Clinical trial results unveiled today at ACTRIMS Forum 2026 suggest that fenebrutinib may be a novel and effective treatment option for people living with primary progressive multiple sclerosis. In this exclusive episode providing the first expert discussion of the complete dataset, FENtrepid trial leads Prof. Amit Bar-Or (University of Pennsylvania) and Dr. Stephen Hauser (University of California San Francisco) break down what the fenebrutinib results really show. Together, they explore: Why BTK inhibition is uniquely positioned to address progressive MS biology How fenebrutinib compared to ocrelizumab in the Phase 3 FENtrepid PPMS trial What the data suggest for patients with non-relapsing, chronic disease Listen for a deep dive into the science and the clinical implications. Editorial Note: At 21:49, the discussion refers to Müller cells. The correct term is Kupffer cells. Download the transcript
More episodes of The ECTRIMS Podcast
- Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
- How MRI and OCT are Changing Multiple Sclerosis Diagnosis, Prognosis, and Treatment
- Does the Label Given to My MS Disease Course Matter?
- Rehabilitation in MS and the Case for Early Intervention
- Harnessing the Gut Microbiome in MS: From Insight to Intervention
- How well are we measuring cognition in MS?
Explore listener stats, chart rankings, contacts and more on the The ECTRIMS Podcast podcast page.